ArticleJournal of gastrointestinal cancer2026
Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePancreatic adenosquamous carcinomas (PASCs) are rare, and their outcomes and prognostic factors have not been fully investigated. This study described treatment outcomes and examined prognostic factors in patients with unresectable PASC who received systemic chemotherapy. In addition, we performed an exploratory comparison of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX) as first-line therapies.
methodsWe retrospectively reviewed the data of 38 patients with unresectable PASC who underwent initial systemic chemotherapy at our institution between January 2007 and April 2023. Overall survival (OS) and progression-free survival were analyzed using the Kaplan-Meier method. Prognostic factors were examined by univariate and multivariate analyses using the Cox proportional hazards model.
resultsThe median patient age was 66 years (52.6% females). Twenty-five patients received GnP, while seven received mFFX as their initial chemotherapy. The median OS for the entire cohort was 12.5 months and the median PFS was 4.5 months. Multivariate analysis identified modified Glasgow prognostic score (mGPS) and peritoneal metastasis as independent factors associated with OS. In the exploratory comparison between the GnP and mFFX groups, no significant differences were observed in OS, PFS, or adverse events.
conclusionmGPS and peritoneal metastasis were independently associated with OS, suggesting the potential importance of nutritional and inflammatory status in patients with unresectable PASC. No significant differences in treatment outcomes were observed between GnP and mFFX regimens.
Indexed as
Identifiers
42192082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.